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Abstract 
Background: McCune-Albright syndrome (MAS) is a rare non-inherited disorder characterized by 
the clinical triad of precocious puberty, cafe-au-lait skin lesions, and fibrous dysplasia of bone. 
Case Presentation: We report a girl with MAS, presenting initially with vaginal bleeding at the age 
of 17 months. Ultrasonography revealed unilateral ovarian cysts and ureteral and ovarian 
enlargement. Considering the clinical and paraclinical findings, the patient diagnosed as a case of 
gonadotropin-independent precocious puberty was treated with medroxy-progestrone acetate 
(MPA) for three months. During the follow up, recurrent episodes of bleeding, ovarian activation 
and cyst formation, as well as breast size development were reported. At the age of 5.5 years, 
fibrous dysplasia was detected, which in coexistence with precocious puberty confirmed the 
diagnosis of MAS. The patient had no cafe-au-lait skin macles during follow up. 
Conclusion: Considering that clinical manifestations of MAS appear later in the course of recurrent 
periods of ovarian activation and cyst formation, a careful clinical observation and follow up of 
patients is necessary and the diagnosis of MAS must be kept in mind in cases with gonadotropin-
independent precocious puberty. 
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Introduction 
McCune-Albright syndrome (MAS) is a rare non-
inherited disorder characterized by the clinical 
triad of precocious puberty, cafe-au-lait skin spots, 
and fibrous dysplasia (FD) of bone[1]. 
     The atypical form consists of only two of these 
conditions. The diagnosis is considered confirmed 
when at least two of the cardinal features are 
present[1]. MAS develops from activation of a post-
zygotic, sporadic or somatic mutation of the 
GNAS1 gene with different clinical manifestations, 
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depending on the tissue carrying the mentioned 
mutations[2]. The prevalence of the syndrome is 
reported to be between 1/100,000-1/1,000,000 
and has been observed more commonly in 
females[3]. 
     The syndrome was first described by Fuller 
Albright at Massachusetts and by Donovan 
McCune at the Columbia University College of 
Physicians and Surgeons in 1936[4]. During the 
time, different reports from MAS have led to better 
understanding of the syndrome and its 
pathophysiology. 
     MAS is also associated with other forms of 
endocrine dysfunction including hyper-
thyroidism, pituitary adenomas (excessive 
secretion of growth hormone, hyperprolactin-
emia), adrenal primary hyperplasia (Cushing 
syndrome), ovarian cysts and hypophosphat-
emia[5]. Gonadal hyperfunction is considered to be 
the most common endocrine dysfunction in 
females, which manifests by precocious puberty, 
vaginal bleeding from the early phase of the 
syndrome to ovarian cysts. It usually presents 
prior to the age of four. 
     It is a gonadotropin-independent phenomen-on 
and vaginal bleeding in these patients occurs as 
early as 3 months of age[6]. 
     Herein, we report a girl with MAS, presenting 
initially with vaginal bleeding at the age of 17 
months. Ovarian cysts were detected during the 
first evaluation and fibrous dysplasia was detected 
during follow up, which confirmed the diagnosis 
MAS. 
Case Presentation 
This patient, a 17-month-old girl, was referred to 
our pediatric endocrinology clinic because of 
vaginal bleeding from three days ago. She had 
normal growth and development and had no 
history of disease. 
     In physical examination, the height was 78.5cm 
(25-50 percentiles) and the weight was 10 kg (25 
percentile). The pubertal stage was B3, according 
to Tanner score. There were no café-au-lait spots, 
and examinations of other organs were normal as 
well. Pelvic ultrasonography revealed 
enlargement of uterus (45×12×20 mm) and 
ovaries (Lt. 16×23 mm and Rt. 32×14 mm) and a 
unilateral ovarian cyst of 15×33 mm of the left 
ovary. Pelvic Magnetic Resonance Imaging (MRI) 
did not reveal any abnormalities and confirmed 
the ultrasonographic results. Routine laboratory 
tests and serum level of LH, FSH, DHEAS, TSH, T4, 
and prolactin gave normal results. Serum estradiol 
(140pg/ml; NL range <10pg/ml) was elevated.  
     Considering the clinical and paraclinical 
findings, the patient diagnosed as a case of 
gonadotropin-independent precocious puberty 
received medroxy-progestrone acetate (MPA) for 
three months. 
     Follow-up investigations revealed regression of 
ovarian cyst and breast size (B2). 
     After 19 months, at age 3, the patient was 
referred again because of vaginal bleeding. Height 
100 cm (95 percentile), weight 15.2 kg (75 
percentile). Bone age was consistent with 5 years. 
Patient had a Tanner score of B3. Pelvic 
ultrasonography revealed enlargement of uterus 
(17×34×54 mm) and ovaries (Lt.11×12 mm and 
Rt.37×35 mm). 
     The results of GnRh test at 30, 60, and 120 min 
were as follow; 
LH= 3 → 4.8 → 5.7 → 7.9     μu/ml;    FSH= 2.9 → 
16 → 16.5 → 18     μu/ml. 
     In order to evaluate the gonadotropin-
dependent precocious puberty, brain MRI was 
performed, which did not reveal any 
abnormalities. The patient received LHRH-agonist 
therapy for two months. The treatment was 
discontinued after that period because of spotting, 
increased breast size, and inappro-priate response 
to LHRH-agonist. 
     During follow-up, the patient had recurrent 
periods of vaginal bleeding and bilateral ovarian 
cysts. In this period she was treated with 
medroxy-progestrone acetate, LHRH-agonist, and 
ciproteron acetate. 
     In order to confirm presence of MAS, when she 
was 5.5 years old, serum levels of Ca, P, cortisol, 
TSH, and T4 were measured in outpatient clinic, 
which gave normal results. 
     In physical examination, height was 127 cm 
(>95 percentile), weight was 28 kg (>95 
percentile), and the bone age was 8.5-9 years. The 
patient had a Tanner score of B3. In face, there 
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was an asymmetry on right and left maxillary 
bones. 
    Radiography of femoral bone was normal but CT 
scan of maxillary bone revealed a fibrous 
dysplasia of the right maxillary bone (Fig. 1 and 2). 
     By coexistence of pseudoprecocious puberty 
and fibrous dysplasia the diagnosis McCune–
Albright syndrome was confirmed. 
Discussion 
The diagnosis of McCune-Albright syndrome 
classically consists of the triad precocious puberty, 
cafe-au-lait skin spots, and fibrous dysplasia of 
bone[1]. The mutation and activation of Gs protein 
alpha subunit is the underlying genetic 
abnormality responsible for the syndrome. MAS 
may have different heterogeneous clinical 
manifestations regarding the number of mutated 
cells and the affected organs[2]. 
     Literature review of the MAS cases indicates 
that most of the previously reported cases of MAS 
were presented as atypical or incomplete forms of 
the syndrome and there were rare cases with the 
classical symptoms. It seems that more practical 
definition of MAS could be any possible 
combination of FD and at least one of the typical 
precocious puberty and cafe-au-lait skin spots as 
reported by other authors[7]. 
     In the current study, we report an atypical case 
of MAS missing cafe-au-lait skin spots. The patient 
was referred with vaginal bleeding and precocious 
puberty. Occurrence of fibrous dysplasia of 
maxillary bone at age 5.5 years confirmed the 
diagnosis MAS. 
     In a case series of MAS in India, there was a 
two-year-and-eight-month-old female with 
vaginal bleeding, cafe-au-lait skin macules, and FD 
of hip and right femur [1]. Our patient had no cafe-
au-lait skin spots.  
     Café au lait spots are large melanotic macules 
without any definitive underlying abnormality. 
Previous studies have indicated that cafe-au-lait 
skin spots occur in approximately 60% of MAS 
cases [8]. In a study, 25% of children aged 6-15 
years had at least one cafe-au-lait skin spot, 
whereas in another study 95% of cases showed 
these lesions [9,10]. It seems that the lesions become 
apparent in future during follow-up period. 
However, prior studies indicated that precocious 
puberty and its related sexual dysfunctions occur 
before the development of bone lesions and skin 
café-au-lait spots [3]. 
     Gonadotropin-independent precocious puberty 
is   considered   as   the  most   common   endocrine 
presentation of the syndrome, which is 
characterized by vaginal bleeding, development of 
   
Fig. 1: Brain CT scan of the patient with gonadotropin-independent precocious puberty and maxillary fibrous 
dysplasia 
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ovarian cysts, and increased breast size. It is 
presented by the sporadic development of 
functional ovarian cysts, which consequently 
result in transient elevations of serum estradiol, 
independent of gonadotropin secretion[11]. 
     Though there are reports of precocious puberty 
in 2- or 9-day-old neonates, it mainly occurs at the 
age of 1-6 years[12-14]. Benedict et al indicated that 
one third of MAS syndrome patients had 
precocious puberty[14], whereas the rate of this 
presentation as the initial clinical sign was 71% in 
the study of Risign et al[15]. Our patient was 
referred because of vaginal bleeding and breast 
enlargement.  
     Fibrous dysplasia, which accounts for 7% of 
total benign bone tumors, is one of the 
components of this syndrome[3]. It may be 
monostotic or polyostotic. It can involve any bone, 
but most commonly affects the long bones, the 
ribs, and the skull. FD in the craniofacial bones 
accounts for 25-35% of all FD cases and usually 
presents as a painless facial-skull asymmetry[16,17]. 
Risign et al and Lumbroso et al, have reported the 
rate of FD to be 98% and 46%, respectively[15,18]. 
Hart et al have investigated the onset and 
presentation of different FD lesions according to 
their location and accordingly have reported that 
FD onset has a region-specific pattern, 90% of 
craniofacial, extremities, and axial skeleton lesions 
were present by 3.4 years, 13.7 years, and 15.5 
years, respectively[19]. But, overall, the median age 
for onset of FD lesions is 6-10 years[19]. In the 
current case report, the age of maxillary FD onset 
was 5.5 years. 
     In a 27-year-old female with MAS, FD was 
presented 24 years after precocious puberty[20]. 
     Computed tomography (CT) scanning 
considered as the gold-standard imaging tool for 
FD, should be repeated annually before the 
stability of the FD lesions[3]. 
     MAS is accompanied by different endocrino-
pathies such as hyperthyroidism, occult 
thyrotoxicosis, hypercortisolism, GH excess and 
hyperprolactinemia. Thyroid disorder is the 
second commonest endocrine disorder. The rate 
of thyroid involvement with and without 
hyperthyroidism is reported to be 19-38% and 
63%, respectively in MAS cases[14,21,22]. The rate of 
Cushing disease, hyperprolactinoma, and GH 
excess in MAS are reported to be 6%, 30-40%, and 
21%, respectively. GH excess is accompanied by 
progression of FD in MAS[2,18,23]. Other endocrine 
disorders associated with MAS are primary 
hyperparathyroidism and hypophos-phateemic 
rickets[2]. None of the above-mentioned endocrine 
disorders were detected in our reported case. 
     Non-endocrine disorders associated with MAS 
are cholestasis, nephrocalcinosis, and cardiac 
involvement[2], which did not exist in the current 
case of MAS. 
Conclusion 
Considering that the clinical manifestations of 
MAS appear later in the course of recurrent 
periods of ovarian activation and cyst formation, a 
careful clinical observation and follow up of 
patients with recurrent episodes of mentioned 
clinical presentations is necessary. Also, the 
diagnosis of MAS must be kept in mind in cases 
with gonadotropin-independent precocious 
puberty, even in the absence of cafe-au-lait skin 
spots. Moreover, different radiologic and 
laboratory assessments should be performed in 
these cases during the follow-up period in order to 
investigate the presence of accompanying 
endocrinological and non-endocrinological 
disorders. 
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